Human Cytomegalovirus Envelope Glycoprotein B (gB) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Human Cytomegalovirus Envelope Glycoprotein B (gB) – Pipeline Review, H2 2017’, provides in depth analysis on Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas under Infectious Disease, Oncology and Women's Health development targeting Human Cytomegalovirus Envelope Glycoprotein B (gB).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Human Cytomegalovirus Envelope Glycoprotein B (gB)

The report reviews Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics and enlists all their major and minor projects

The report assesses Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Human Cytomegalovirus Envelope Glycoprotein B (gB)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Human Cytomegalovirus Envelope Glycoprotein B (gB) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Astellas Pharma Inc

Merck & Co Inc

Novartis AG

Trellis Bioscience Inc

Vakzine Projekt Management GmbH

VBI Vaccines Inc

Vical Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Overview 6

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 10

Products under Development by Universities/Institutes 12

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Assessment 14

Assessment by Mechanism of Action 14

Assessment by Route of Administration 15

Assessment by Molecule Type 17

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Companies Involved in Therapeutics Development 19

Astellas Pharma Inc 19

Merck & Co Inc 19

Novartis AG 20

Trellis Bioscience Inc 20

Vakzine Projekt Management GmbH 20

VBI Vaccines Inc 21

Vical Inc 21

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drug Profiles 23

ASP-0113 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

Bispecific Monoclonal Antibody to Target CD3 and gB for Cytomegalovirus (HHV-5) Infections - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

CSJ-148 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

CyMVectin - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Cytomegalovirus vaccine - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

PPCM - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

TRL-345 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

VBI-1501A - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

VBI-1901 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

VPM-2001 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Dormant Products 40

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Product Development Milestones 41

Featured News & Press Releases 41

Nov 10, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017 41

Oct 11, 2017: VBI Vaccines to Present Phase 1 CMV vaccine data at The World Vaccine Congress Europe 2017 in Barcelona 41

Oct 10, 2017: Vical Announces Completion of the Phase 3 ASP0113 CMV Vaccine Trial 41

Aug 28, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit 42

Aug 15, 2017: VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme 42

Jul 27, 2017: VBI Vaccines Announces Positive Interim Data from Phase 1 Study of Preventative CMV Vaccine 43

May 02, 2017: VBI Vaccines Provides Update on its Congenital CMV Phase I Clinical Study 44

Apr 05, 2017: VBI Vaccines to Present Update on VBI-1901 at the World Vaccine Congress 44

Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting 45

Oct 11, 2016: VBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate 45

Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe 46

Sep 20, 2016: Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus Vaccine (ASP0113) in Kidney Transplant Patients 46

Sep 20, 2016: VBI Vaccines Completes Enrollment of Participants in the Phase I Clinical Trial of its Preventative Cytomegalovirus Vaccine Candidate 47

Sep 01, 2016: VBI Vaccines to Present at the Vaccine Congress 47

Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit 48

Appendix 50

Methodology 50

Coverage 50

Secondary Research 50

Primary Research 50

Expert Panel Validation 50

Contact Us 50

Disclaimer 51

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indication, H2 2017 9

Number of Products under Development by Companies, H2 2017 10

Products under Development by Companies, H2 2017 11

Number of Products under Investigation by Universities/Institutes, H2 2017 12

Products under Investigation by Universities/Institutes, H2 2017 13

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Stage and Route of Administration, H2 2017 16

Number of Products by Stage and Molecule Type, H2 2017 18

Pipeline by Astellas Pharma Inc, H2 2017 19

Pipeline by Merck & Co Inc, H2 2017 19

Pipeline by Novartis AG, H2 2017 20

Pipeline by Trellis Bioscience Inc, H2 2017 20

Pipeline by Vakzine Projekt Management GmbH, H2 2017 21

Pipeline by VBI Vaccines Inc, H2 2017 21

Pipeline by Vical Inc, H2 2017 22

Dormant Projects, H2 2017 40

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indications, H2 2017 9

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Routes of Administration, H2 2017 15

Number of Products by Stage and Routes of Administration, H2 2017 15

Number of Products by Molecule Types, H2 2017 17

Number of Products by Stage and Molecule Types, H2 2017 17

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports